 BRISBANE, Calif.--BUSINESS WIRE--Sangamo Therapeutics, Inc. Nasdaq: SGMO, a genomic medicine company, today announced that the European Medicines Agencys Committee for Orphan Medicinal Products COMP released details supporting the Orphan Designation of BIVV003, an investigational ex vivo gene-edited cell therapy product candidate currently being evaluated for the treatment of sickle cell disease in the Phase 12 PRECIZN-1 study partnered with Sanofi. The Committees decision to grant Orp 